For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Nantkwest Inc.

USPTO Granted Patents = 17

CIPO Patents = 1

EPO Patents = 2

Trademarks = 14

Forward Citations = 92

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Hans G Klingemann (14 out of 39 patents)

Laurent H Boissel (9 out of 28 patents)

Barry J Simon (7 out of 16 patents)

4. Patrick Soon-Shiong (4 out of 447 patents)

5. Tien Lee (4 out of 7 patents)

6. John H Lee (2 out of 12 patents)

7. Nathan T Schomer (2 out of 3 patents)

8. Jeffrey Safrit (1 out of 5 patents)

9. Abhijit Dandapat (1 out of 5 patents)

10. Kayvan R Niazi (1 out of 90 patents)

11. James N Woody (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 12427152 - HDAC inhibitors for use with NK cell based therapies (2025-09-30),

2. 12303477 - HIV treatment compositions and methods (2025-05-20),

3. 11077143 - Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells (2021-08-03),

4. 11058723 - Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies (2021-07-13),

5. 11000550 - Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer (2021-05-11),

6. 10960024 - Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies (2021-03-30),

7. 10801013 - Modified NK-92 haNK003 cells for the clinic (2020-10-13),

8. 10774310 - Modified NK-92 haNK003 cells for the clinic (2020-09-15),

9. 10772912 - Tumoricidal and antimicrobial composition (2020-09-15),

10. 10765701 - Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells (2020-09-08),

11. 10738279 - Modified NK-92 cells for treating cancer (2020-08-11),

12. 10736921 - Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer (2020-08-11),

13. 10646516 - Tumoricidal and antimicrobial compositions and methods (2020-05-12),

14. 10517895 - Tumoricidal and antimicrobial compositions and methods (2019-12-31),

15. 10456420 - Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer (2019-10-29),

NantKwest Inc. is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the natural killer (NK) cell to treat cancer and infectious diseases. With a mission to design novel, off-the-shelf cell therapies that engage the innate immune system, NantKwest aims to transform treatment paradigms by targeting multiple tumors simultaneously and delivering long-term, durable responses for patients. Visit our website to learn more about our cutting-edge research and therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#326 in San Diego, CA

#4,375 in California

#18,334 in US

#34,861 in the World

San Diego, CA, United States of America

Nantkwest Inc.

Forward Citations = 92

11 inventors:

Hans G Klingemann (14 out of 39 patents)

Laurent H Boissel (9 out of 28 patents)

Barry J Simon (7 out of 16 patents)

4. Patrick Soon-Shiong (4 out of 447 patents)

5. Tien Lee (4 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…